693 related articles for article (PubMed ID: 22005114)
21. Nuclear medicine in the detection and management of pancreatic islet-cell tumours.
Virgolini I; Traub-Weidinger T; Decristoforo C
Best Pract Res Clin Endocrinol Metab; 2005 Jun; 19(2):213-27. PubMed ID: 15763696
[TBL] [Abstract][Full Text] [Related]
22. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues.
Kwekkeboom DJ; Teunissen JJ; Kam BL; Valkema R; de Herder WW; Krenning EP
Hematol Oncol Clin North Am; 2007 Jun; 21(3):561-73; x. PubMed ID: 17548040
[TBL] [Abstract][Full Text] [Related]
23. Diagnostics of neuroendocrine tumours.
Hodolic M; Fettich J; Banti E; Chondrogiannis S; Al-Nahhas A; Rubello D
In Vivo; 2010; 24(5):771-4. PubMed ID: 20952747
[TBL] [Abstract][Full Text] [Related]
24. Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?
van Adrichem RC; Kamp K; van Deurzen CH; Biermann K; Feelders RA; Franssen GJ; Kwekkeboom DJ; Hofland LJ; de Herder WW
Neuroendocrinology; 2016; 103(5):560-6. PubMed ID: 26536001
[TBL] [Abstract][Full Text] [Related]
25. Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy.
Wiedenmann B; Bäder HM; Scherubl H; Fett U; Zimmer T; Hamm B; Koppenhagen K; Riecken EO
Semin Oncol; 1994 Oct; 21(5 Suppl 13):29-32. PubMed ID: 7992077
[No Abstract] [Full Text] [Related]
26. Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours.
Gibril F; Jensen RT
Dig Liver Dis; 2004 Feb; 36 Suppl 1():S106-20. PubMed ID: 15077919
[TBL] [Abstract][Full Text] [Related]
27. Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors.
Giovacchini G; Nicolas G; Forrer F
Anticancer Agents Med Chem; 2012 Jun; 12(5):526-42. PubMed ID: 22292758
[TBL] [Abstract][Full Text] [Related]
28. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Valkema R; Pauwels S; Kvols LK; Barone R; Jamar F; Bakker WH; Kwekkeboom DJ; Bouterfa H; Krenning EP
Semin Nucl Med; 2006 Apr; 36(2):147-56. PubMed ID: 16517236
[TBL] [Abstract][Full Text] [Related]
29. GEP-NETS update: functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs).
de Herder WW
Eur J Endocrinol; 2014 May; 170(5):R173-83. PubMed ID: 24723670
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis.
Treglia G; Castaldi P; Rindi G; Giordano A; Rufini V
Endocrine; 2012 Aug; 42(1):80-7. PubMed ID: 22350660
[TBL] [Abstract][Full Text] [Related]
31. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
32. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
33. Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy.
Teunissen JJ; Kwekkeboom DJ; de Jong M; Esser JP; Valkema R; Krenning EP
Best Pract Res Clin Gastroenterol; 2005 Aug; 19(4):595-616. PubMed ID: 16183530
[TBL] [Abstract][Full Text] [Related]
34. Targeted radiotherapy with radiolabeled somatostatin analogs.
Nicolas G; Giovacchini G; Müller-Brand J; Forrer F
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):187-204, ix-x. PubMed ID: 21349419
[TBL] [Abstract][Full Text] [Related]
35. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
36. Current status and perspectives in peptide receptor radiation therapy.
Ansquer C; Kraeber-Bodéré F; Chatal JF
Curr Pharm Des; 2009; 15(21):2453-62. PubMed ID: 19601842
[TBL] [Abstract][Full Text] [Related]
37. [Diagnostics and treatment of neuroendocrine tumors of the digestive tract in the light of the present standards].
Szczeblowska D
Pol Merkur Lekarski; 2007 May; 22(131):437-41. PubMed ID: 17679390
[TBL] [Abstract][Full Text] [Related]
38. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
Baumann T; Rottenburger C; Nicolas G; Wild D
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):45-57. PubMed ID: 26971843
[TBL] [Abstract][Full Text] [Related]
39. Tumor response assessment to treatment with [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors: differential response of bone versus soft-tissue lesions.
van Vliet EI; Hermans JJ; de Ridder MA; Teunissen JJ; Kam BL; de Krijger RR; Krenning EP; Kwekkeboom DJ
J Nucl Med; 2012 Sep; 53(9):1359-66. PubMed ID: 22782312
[TBL] [Abstract][Full Text] [Related]
40. Quantitative SPECT/CT for Dosimetry of Peptide Receptor Radionuclide Therapy.
Kennedy J; Chicheportiche A; Keidar Z
Semin Nucl Med; 2022 Mar; 52(2):229-242. PubMed ID: 34911637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]